Can-Fite BioPharma (NYSE:CANF) Upgraded to “Hold” by StockNews.com

Can-Fite BioPharma (NYSE:CANF) was upgraded by equities researchers at StockNews.com from a “sell” rating to a “hold” rating in a note issued to investors on Tuesday.

Separately, EF Hutton Acquisition Co. I raised shares of Can-Fite BioPharma to a “strong-buy” rating in a research note on Wednesday, July 17th.

Can-Fite BioPharma Stock Performance

NYSE:CANF opened at $2.65 on Tuesday. The firm has a market capitalization of $9.38 million, a PE ratio of -1.48 and a beta of 1.41. The stock’s fifty day moving average is $2.30 and its 200 day moving average is $2.51. Can-Fite BioPharma has a fifty-two week low of $1.81 and a fifty-two week high of $4.69.

Institutional Inflows and Outflows

An institutional investor recently raised its position in Can-Fite BioPharma stock. Armistice Capital LLC grew its stake in Can-Fite BioPharma Ltd. (NYSE:CANF) by 35.5% during the second quarter, according to its most recent 13F filing with the Securities and Exchange Commission (SEC). The institutional investor owned 518,853 shares of the company’s stock after acquiring an additional 136,055 shares during the period. Armistice Capital LLC owned 14.66% of Can-Fite BioPharma worth $1,339,000 at the end of the most recent reporting period. 21.00% of the stock is currently owned by institutional investors and hedge funds.

Can-Fite BioPharma Company Profile

Can-Fite BioPharma Ltd., a clinical-stage biopharmaceutical company, develops small molecule therapeutic products for the treatment of cancer, liver inflammatory diseases, and erectile dysfunction. The company's lead drug candidate Piclidenoson, which has been completed Phase III clinical trial for the treatment of psoriasis; and Phase II clinical trial for the treatment of COVID-19.